Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling.
about
The molecular mechanism of Noxa-induced mitochondrial dysfunction in p53-mediated cell deathIdentification and characterization of the cytoplasmic protein TRAF4 as a p53-regulated proapoptotic geneBID regulation by p53 contributes to chemosensitivityMutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy.Tumor necrosis factor alpha sensitizes malignant cells to chemotherapeutic drugs via the mitochondrial apoptosis pathway independently of caspase-8 and NF-kappaB.Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression.Tumor associated macrophages protect colon cancer cells from TRAIL-induced apoptosis through IL-1beta-dependent stabilization of Snail in tumor cells.Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinomaGossypol induces death receptor-5 through activation of the ROS-ERK-CHOP pathway and sensitizes colon cancer cells to TRAILRequirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.Synergistic induction of cell death in liver tumor cells by TRAIL and chemotherapeutic drugs via the BH3-only proteins Bim and BidCasticin potentiates TRAIL-induced apoptosis of gastric cancer cells through endoplasmic reticulum stress.Oncolytic adenoviruses: A thorny path to glioma cureThe role of p53 in chemosensitivity and radiosensitivity.TRAIL and apoptosis induction by TNF-family death receptors.3,3'-diindolylmethane potentiates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of gastric cancer cells.CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice.Identification of signaling pathways mediating cell cycle arrest and apoptosis induced by Porphyromonas gingivalis in human trophoblastsCytokines, inflammation and colon cancerTRAIL receptor-targeted therapy.N-Myc downstream-regulated gene 2 is involved in p53-mediated apoptosis.Structural insights of homotypic interaction domains in the ligand-receptor signal transduction of tumor necrosis factor (TNF).Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia proteinDirect repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity.Mitochondrial signaling in cell death via the Bcl-2 family.Plumbagin treatment leads to apoptosis in human K562 leukemia cells through increased ROS and elevated TRAIL receptor expression.Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.Isosilybin A induces apoptosis in human prostate cancer cells via targeting Akt, NF-κB, and androgen receptor signalingLactobacillus strains induce TRAIL production and facilitate natural killer activity against cancer cells.Synergistic anti-cancer activity by the combination of TRAIL/APO-2L and celastrol.Ethanolic extract of Thevetia peruviana flowers enhances TNF-α and TRAIL-induced apoptosis of human cervical cancer cells via intrinsic and extrinsic pathways.Nitric oxide inhibition of homocysteine-induced human endothelial cell apoptosis by down-regulation of p53-dependent Noxa expression through the formation of S-nitrosohomocysteine.Cathepsin B mediates TRAIL-induced apoptosis in oral cancer cells.p53: 25 years of research and more questions to answer.Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor
P2860
Q24294863-6A75D836-B87E-4104-A564-81C56686EB27Q28177158-C8AD1DCE-3D46-4413-A9EC-D16AC87ADE19Q28211208-7271E8CB-65A1-4631-987F-FC114CC56D6AQ33186850-E6EDF0F2-9D3C-43FA-9413-F013A99A3ACCQ33205160-FBCDB216-5A86-4CC7-9C6A-66C3372B271DQ33288897-EE9EAD74-80DB-4218-A913-F2C7F4C481DDQ33641541-420ACFB1-68D6-4C9E-B830-B099D477BAB0Q33811260-1F6D379F-60C6-4C9A-B823-4EFBB0C8C68BQ34285051-C9A4E005-CC8C-496F-84FE-D9558C41F27BQ34390964-72C315B2-09A3-4146-AFD5-904DAC325F34Q34561806-E6C1538A-B519-43DF-AFAD-37E8C389BAD6Q34639429-E6021107-98CE-471D-B3D7-537C669B12DDQ35077747-950BE5BE-8BA6-4F10-8353-8159BE11C88CQ35567279-B1F9F507-314D-4A90-BBEA-DE82F3CF0866Q35591708-CAB89EC7-83DB-4FA0-B0F3-B4219D0AA74BQ35742296-321AC7F6-39A7-4C13-BCA0-4C7AFD2F2324Q36173604-6FAB0E5D-F3BA-4260-A737-F7995BE8C2AFQ36211069-2DDC994D-1C4B-4B8C-A40B-2501BEE5831DQ36520856-AA1062C5-E5B3-4441-8601-1397E0351CA8Q36572530-7B7A6899-0664-437A-9CFA-D00E4856EE0BQ36868501-6C3CA4EB-B9E2-4292-9051-33E4E5A92040Q37024785-820A9821-CBB1-4A2D-8C36-A52FEF9129FAQ37290808-1239860A-C1FD-49DF-A15B-C89953E833DBQ37515926-9B2E68C0-582D-410B-AB0E-C6D9BEA00C55Q37700096-8C168F60-2FD5-48FA-A8DB-625E9A3B2EB4Q38271097-B6AC407B-9F2B-4295-B93B-FF46D1B5CA07Q38309479-B0A75B6F-A644-4B6C-833C-C0B379D22191Q39665818-774ECA7F-DCCF-4E74-AB16-617AD13C5EFBQ39765675-B913D73F-7F43-45DC-B6B7-A589663280D9Q39774066-CB552046-86DE-48D5-8F23-4F3EE6DAF0A8Q42176172-9710C6F4-0659-4F57-9155-C63990F7F38CQ45161114-24AA0056-E60E-4618-A6D8-03A44AE1EA1FQ49189903-38916241-D122-42CD-B2AF-D9F0F20B25C6Q53380051-7BFF1783-AEC6-4E14-B937-8F2A3D03BB78Q57137831-E353A185-DAC8-427E-848C-92F2A8534396
P2860
Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling.
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling.
@ast
Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling.
@en
Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling.
@nl
type
label
Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling.
@ast
Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling.
@en
Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling.
@nl
prefLabel
Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling.
@ast
Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling.
@en
Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling.
@nl
P2860
P356
P1476
Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling.
@en
P2093
El-Deiry WS
P2860
P2888
P304
P356
10.1038/SJ.CDD.4400943
P577
2001-11-01T00:00:00Z
P5875
P6179
1031009974